loading page

Safety Analysis of High-Dose Methotrexate in Pediatric Non-Hodgkin Lymphomas
  • +3
  • Melanie Bernhardt,
  • Austin Brown,
  • Austyn Grim,
  • Michael Scheurer,
  • Nader El-Mallawany,
  • Nmazuo Ozuah
Melanie Bernhardt
Baylor College of Medicine

Corresponding Author:mbbernha@txch.org

Author Profile
Austin Brown
Baylor College of Medicine
Author Profile
Austyn Grim
Texas Children's Hospital
Author Profile
Michael Scheurer
Baylor College of Medicine Department of Pediatrics
Author Profile
Nader El-Mallawany
Baylor College of Medicine
Author Profile
Nmazuo Ozuah
Baylor College of Medicine
Author Profile


High-dose methotrexate (HD-MTX) with rigorous supportive care is essential to the treatment of pediatric non-Hodgkin lymphomas (NHL). We describe the safety and tolerability of HD-MTX in patients with NHL treated at our center. In our cohort of 46 patients, the majority had at least one course of delayed clearance and/or creatinine elevation. Additionally, more than one-third of patients experienced an episode of grade ≥3 mucositis. Creatinine elevations and delayed clearance were independently associated with subsequent grade ≥3 mucositis. We advocate for greater availability of methotrexate monitoring to allow dose escalation of this essential modality around the world.
09 Mar 2022Submitted to Pediatric Blood & Cancer
09 Mar 2022Submission Checks Completed
09 Mar 2022Assigned to Editor
10 Mar 2022Reviewer(s) Assigned
16 Apr 2022Review(s) Completed, Editorial Evaluation Pending
16 Apr 2022Editorial Decision: Revise Major
31 Jul 2022Submission Checks Completed
31 Jul 2022Assigned to Editor
31 Jul 20221st Revision Received
01 Aug 2022Review(s) Completed, Editorial Evaluation Pending
01 Aug 2022Editorial Decision: Accept
Nov 2022Published in Pediatric Blood & Cancer volume 69 issue 11. 10.1002/pbc.29940